Breath Therapeutics Inc   Report issue

For profit Phase 3
Founded: Munich Germany (2017)
Status: Acquired by Zambon (2019)

Organization Overview

First Clinical Trial
2019
NCT03657342
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Breath Therapeutics - a Zambon Company | Breath Therapeutics, Chief Medical Officer | Breath Therapeutics Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

cyclosporine (sandimmune) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchiolitis (Phase 3)

Bronchiolitis Obliterans (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1